UnitedHealthcare · Semaglutide · US health-plan appeal rights

Semaglutide denied for missing prior authorization by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-05-04

At a glance

Why does UHC require prior authorization on semaglutide?

Branded semaglutide (Wegovy, Ozempic, Rybelsus) requires PA on most UHC plans for adults ≥18 to satisfy OptumRx's GLP-1 PA Guideline criteria — BMI, comorbidity, lifestyle modification, step therapy.

What documentation does the OptumRx PA require?

BMI in past 12 months, comorbidity ICD-10 code, 6-month lifestyle modification program with frequency/content/progress, step-therapy trial with dates and outcomes, and continuation criterion (≥5% weight loss at 6 months for renewals).

What's the most common reason a PA fails?

Comorbidity documented as narrative description rather than ICD-10 code (E66.01, I10, E78.5, E11.9, G47.33). OptumRx's automated review uses checklist matching and rejects narrative descriptions.

How do I avoid a treatment gap during PA renewal?

Request a 7-day bridge supply on appeal — OptumRx's continuity-of-care policy permits this. Submit the renewal at least 14 days before the current PA expires.

How long does ERISA give UHC to decide a PA appeal?

72 hours for urgent-care under 29 CFR §2560.503-1(f)(2)(i) when the patient is currently on the medication; otherwise standard timelines apply.

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

BMI >=30, OR BMI >=27 with at least one weight-related comorbidity (T2DM, hypertension, dyslipidemia, CVD, OSA). 6-month documented diet/exercise program. Step therapy: failed/contraindicated phentermine/topiramate or Contrave trial.

Source policy: GLP-1 Receptor Agonists for Weight Management

What works in the appeal

Step-therapy: Document contraindications to required agents - phentermine contraindicated in cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, MAOI use within 14 days (FDA prescribing information); phentermine/topiramate contraindicated in pregnancy, glaucoma, hyperthyroidism, MAOI use (FDA prescribing information); naltrexone/bupropion contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, chronic opioid use, abrupt discontinuation of alcohol/benzodiazepines (FDA prescribing information). If prior trial completed: document inadequate response (weight loss <5% after 12 weeks per 2016 AACE/ACE obesity guidelines) or intolerance with specific adverse effects (e.g., tachycardia, insomnia, nausea, headache). Cite semaglutide 2.4mg FDA approval for chronic weight management in adults with obesity or overweight with weight-related comorbidity (June 2021). Reference STEP 1 trial showing semaglutide produced mean 14.9% body weight reduction vs 2.4% with placebo at 68 weeks (NEJM 2021;384:989-1002). Cite AMA recognition of obesity as a disease requiring treatment (2013) and 2016 AACE/ACE obesity algorithm supporting GLP-1 receptor agonists when lifestyle and first-line pharmacotherapy fail or are contraindicated. BMI threshold: Verify FDA indication (BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia). Supervised program: Document prior lifestyle intervention attempts including dietary counseling and increased physical activity per FDA indication requirements. Employer carve-out: Request plan documents confirming exclusion; appeal as medically necessary treatment for chronic disease; consider state parity laws if applicable.

The UnitedHealthcare angle on Semaglutide

When UHC tags semaglutide "prior auth required" as a denial reason, the issue is procedural — the prior auth was either never submitted, submitted incomplete, expired without renewal, or routed to the wrong channel. The drug isn't being denied on clinical grounds; the paperwork didn't satisfy OptumRx's PA criteria checklist.

Fix it as a re-submission, not a clinical appeal. Pull the OptumRx GLP-1 PA form (specific to the prescriber's state and plan) and complete every field with chart documentation:

BMI documented in past 12 months with the exact visit date and the measured (not calculated) BMI from clinical visit.
Comorbidity ICD-10 code rather than narrative — E66.01 morbid obesity, I10 hypertension, E78.5 dyslipidemia, E11.9 T2DM, G47.33 obstructive sleep apnea, M16 hip osteoarthritis, M17 knee osteoarthritis, K90.81 NAFLD. OptumRx's automated review rejects narrative descriptions.
6-month lifestyle modification program with frequency (monthly visits with prescriber, RD, exercise physiologist, or behavioral health), content (specific calorie target like 1,500 kcal/day, exercise prescription such as 150 min/week moderate aerobic + 2x/week resistance, behavioral intervention component), and progress (weight at each visit with documented trajectory).
Step-therapy documentation for phentermine/topiramate or Contrave with specific dates, doses, and outcomes — OR a chart-cited contraindication with the visit date.
Continuation criterion if the request is for renewal: ≥5% weight loss at 6 months with explicit starting weight and current weight.

UHC's automated PA review uses strict checklist matching. A field with "yes" but no supporting documentation gets flagged as incomplete and the auto-denial fires. Always attach the chart documentation that supports each yes.

If the patient is currently on the medication and the PA expired without renewal, UHC's policy provides a 7-day bridge supply on appeal — request it explicitly with the expedited tag to avoid treatment interruption.

The federal regulatory hook: UHC must provide written notice of any documentation requirement before denial under ERISA §503(g). If the auto-denial fired without listing what was missing, the appeal can compel the disclosure under 29 CFR §2560.503-1(g)(1)(iv) and restart the PA clock.

Closing tactical tip: submit the PA renewal at least 14 days before the current authorization expires — OptumRx's automated processing has queue depth that adds 5-7 days to standard review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Semaglutide

Other denial reasons for UnitedHealthcare Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.